相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2022)
Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies
Jomjit Chantharasamee et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma
Dongjun Dai et al.
FRONTIERS IN GENETICS (2021)
Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
Lina Marie Hoffmeister et al.
CANCERS (2021)
A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model
Karolina Uranowska et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2021)
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
Ricarda M. Hoffmann et al.
CANCERS (2020)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Valeria Leuci et al.
CLINICAL CANCER RESEARCH (2020)
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
Jeffrey C. Thompson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
A. Dufresne et al.
ONCOIMMUNOLOGY (2020)
Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response
Maria A. Pantaleo et al.
ONCOIMMUNOLOGY (2019)
CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges
Dennis C. Harrer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage
Shu-Hsuan Claire Hsu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Chondroitin Sulfate Proteoglycan 4 and its Potential As an Antibody immunotherapy Target across Different Tumor Types
Kristina M. Ilieva et al.
FRONTIERS IN IMMUNOLOGY (2018)
The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
Francois Bertucci et al.
BRITISH JOURNAL OF CANCER (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
Wouter Hendrickx et al.
ONCOIMMUNOLOGY (2017)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
Hideo Komita et al.
ONCOLOGY REPORTS (2015)
Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis
Le-Le Lu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
PDL1 expression is an independent prognostic factor in localized GIST
Francois Bertucci et al.
ONCOIMMUNOLOGY (2015)
Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
Agnieszka Wozniak et al.
CLINICAL CANCER RESEARCH (2014)
Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients
Rolf Warta et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer
Nicholas C. Hsu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Sylvie Rusakiewicz et al.
CANCER RESEARCH (2013)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor
Steven C. Katz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy
Heikki Joensuu et al.
ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Heikki Joensuu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
Agnete Svendsen et al.
ACTA NEUROPATHOLOGICA (2011)
Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
Domenico Coppola et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Natural History of Imatinib-naive GISTs: A Retrospective Analysis of 929 Cases With Long-term Follow-up and Development of a Survival Nomogram Based on Mitotic Index and Size as Continuous Variables
Sabrina Rossi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Navigating Risk Stratification Systems for the Management of Patients With GIST
Shreyaskumar Patel
ANNALS OF SURGICAL ONCOLOGY (2011)
The GIST paradigm: lessons for other kinase-driven cancers
Cristina R. Antonescu
JOURNAL OF PATHOLOGY (2011)
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye et al.
NATURE MEDICINE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
Matthew A. Price et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors
Minka van Dongen et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Xinhui Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
A pathway-based classification of human breast cancer
Michael L. Gatza et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
Cedric Menard et al.
CANCER RESEARCH (2009)
NG2 Expression Predicts the Metastasis Formation in Soft-Tissue Sarcoma Patients
Maria Serena Benassi et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Lori Rink et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
Jason S. Gold et al.
LANCET ONCOLOGY (2009)
Immune cells in primary gastrointestinal stromal tumors
Silke Cameron et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2008)
Gastrointestinal stromal tumors: Pathology and prognosis at different sites
Markku Miettinen et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
分享论文
